Innoviva, Inc. (INVA): Total Assets
$1.64B
As of 2025-12-31
$1.70B
As of 2026-06-30
+9.9%
3-year compound annual growth
+10.3%
5-year compound annual growth
+14.9%
10-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $1.64B | +25.7% | 2026-02-25, Balance as of period end |
| 2024-12-31 | $1.30B | +4.6% | 2026-02-25, Balance as of period end |
| 2023-12-31 | $1.24B | +1.0% | 2025-02-26, Balance as of period end |
| 2022-12-31 | $1.23B | +32.9% | 2024-03-05, Balance as of period end |
| 2021-12-31 | $926.39M | -7.3% | 2023-02-28, Balance as of period end |
| 2020-12-31 | $999.57M | +37.9% | 2022-03-17, Balance as of period end |
| 2019-12-31 | $724.83M | +32.2% | 2021-02-25, Balance as of period end |
| 2018-12-31 | $548.19M | +49.2% | 2020-02-19, Balance as of period end |
| 2017-12-31 | $367.34M | -3.1% | 2019-02-19, Balance as of period end |
| 2016-12-31 | $379.00M | -7.3% | 2018-02-23, Balance as of period end |
| 2015-12-31 | $408.93M | n/c | 2017-02-28, Balance as of period end |
| 2014-12-31 | $521.65M | -23.4% | 2016-02-24, Balance as of period end |
| 2013-12-31 | $681.25M | +84.8% | 2015-02-27, Balance as of period end |
| 2012-12-31 | $368.58M | +42.4% | 2014-03-03, Balance as of period end |
| 2011-12-31 | $258.78M | -21.9% | 2013-02-26, Balance as of period end |
| 2010-12-31 | $331.20M | n/a | 2012-02-27, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Innoviva, Inc. (INVA) | 2025-12-31 | $1.64B | +25.7% |
| Ardelyx, Inc. (ARDX) | 2025-12-31 | $501.60M | +15.1% |
| Sinovac Biotech Ltd (SVA) | 2025-12-31 | $8.54B | -30.8% |
| Arcutis Biotherapeutics, Inc. (ARQT) | 2025-12-31 | $432.97M | +24.1% |
| Zai Lab Ltd (ZLAB) | 2025-12-31 | $1.17B | -1.1% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $261.15M | +8.4% |
| MannKind Corp (MNKD) | 2025-12-31 | $792.18M | +101.1% |
| Travere Therapeutics, Inc. (TVTX) | 2025-12-31 | $605.19M | +1.9% |
| BridgeBio Pharma, Inc. (BBIO) | 2025-12-31 | $936.02M | +1.8% |
Compare INVA, ARDX, SVA, ARQT side by side · Screen every company in Pharmaceutical Preparations ↗